JP2010534486A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534486A5
JP2010534486A5 JP2010518606A JP2010518606A JP2010534486A5 JP 2010534486 A5 JP2010534486 A5 JP 2010534486A5 JP 2010518606 A JP2010518606 A JP 2010518606A JP 2010518606 A JP2010518606 A JP 2010518606A JP 2010534486 A5 JP2010534486 A5 JP 2010534486A5
Authority
JP
Japan
Prior art keywords
albumin
binding polypeptide
complex
compound
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010518606A
Other languages
English (en)
Japanese (ja)
Other versions
JP5718638B2 (ja
JP2010534486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/059389 external-priority patent/WO2009016043A2/en
Publication of JP2010534486A publication Critical patent/JP2010534486A/ja
Publication of JP2010534486A5 publication Critical patent/JP2010534486A5/ja
Application granted granted Critical
Publication of JP5718638B2 publication Critical patent/JP5718638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010518606A 2007-07-31 2008-07-17 新規な組成物、方法および使用 Active JP5718638B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
US60/962,618 2007-07-31
EP07113533 2007-07-31
EP07113533.9 2007-07-31
PCT/EP2008/059389 WO2009016043A2 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Publications (3)

Publication Number Publication Date
JP2010534486A JP2010534486A (ja) 2010-11-11
JP2010534486A5 true JP2010534486A5 (enExample) 2011-08-18
JP5718638B2 JP5718638B2 (ja) 2015-05-13

Family

ID=40057660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518606A Active JP5718638B2 (ja) 2007-07-31 2008-07-17 新規な組成物、方法および使用

Country Status (11)

Country Link
US (2) US8937153B2 (enExample)
EP (2) EP2190863B1 (enExample)
JP (1) JP5718638B2 (enExample)
CN (2) CN104710518A (enExample)
AU (1) AU2008281913B2 (enExample)
CA (1) CA2694139C (enExample)
DE (1) DE08786222T1 (enExample)
DK (1) DK2190863T3 (enExample)
ES (1) ES2346178T3 (enExample)
HK (1) HK1211040A1 (enExample)
WO (1) WO2009016043A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008281913B2 (en) * 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
US9175067B2 (en) * 2010-03-08 2015-11-03 Ge Healthcare Bio-Sciences Ab Immunoglobulin G Fc region binding polypeptide
MX2012012383A (es) * 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
EP2933262B1 (en) * 2010-07-09 2018-05-02 Affibody AB Polypeptides
EP2601216B1 (en) * 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
AU2011333666B2 (en) 2010-11-26 2017-02-02 Molecular Partners Ag Improved capping modules for designed ankyrin repeat proteins
UA111612C2 (uk) * 2011-05-21 2016-05-25 Макродженікс, Інк. Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці
PT2729160T (pt) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
WO2013009545A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
AU2013222836B2 (en) 2012-02-20 2017-07-20 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement C5
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
EP2844269A4 (en) * 2012-03-28 2016-01-06 Amylin Pharmaceuticals Llc TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
MX355041B (es) 2012-05-25 2018-03-28 Janssen Biotech Inc Dominios de union a albumina consenso no naturales.
WO2014048977A1 (en) * 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
JP6440618B2 (ja) 2012-10-05 2018-12-19 アフィボディ・アーベー Her3結合ポリペプチド
JP6382826B2 (ja) * 2012-10-25 2018-08-29 アフィボディ・アーベー アルブミン結合ポリペプチド
EP2912051B1 (en) * 2012-10-25 2018-04-18 Affibody AB Method for the separation of proteins containing an albumin-binding domain
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
WO2014140882A2 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
CA2905186A1 (en) 2013-03-14 2014-09-18 Daiichi Sankyo Co., Ltd Novel binding proteins for pcsk9
CN105209482B (zh) 2013-03-15 2022-04-29 阿菲博迪公司 新的多肽
WO2014172392A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
RU2714156C2 (ru) 2013-08-28 2020-02-12 Аффибоди Аб С5-связующие полипептиды
HRP20210013T1 (hr) 2013-08-28 2021-04-02 Ipc Research, Llc Stabilni polipeptidi koji se vezuju za ljudski komplement c5
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CR20170027A (es) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
ES2744588T3 (es) 2014-09-17 2020-02-25 Affibody Ab Nuevos polipéptidos
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
WO2016113246A1 (en) 2015-01-12 2016-07-21 Affibody Ab Il-17a-binding polypeptides
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン10の使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
EP3515928A4 (en) 2016-09-23 2020-04-01 Duke University UNSTRUCTURED NON-REPITITIVE POLYPEPTIDES WITH LCST BEHAVIOR
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
EP3691693A4 (en) 2017-10-06 2021-08-25 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
WO2019147954A1 (en) * 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US11505576B2 (en) 2018-03-13 2022-11-22 Affibody Ab Polypeptides based on a scaffold
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US20210316007A1 (en) * 2018-09-07 2021-10-14 Duke University Nanoparticulate drug delivery systems
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
KR20220016944A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 개선된 안정성을 갖는 설계된 안키린 반복 도메인
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4017521A1 (en) 2019-09-02 2022-06-29 Biotest AG Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) * 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
JP2023554258A (ja) 2020-12-21 2023-12-27 アフィボディ アクティエボラーグ 新規のポリペプチド
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
EP4476247A1 (en) 2022-02-08 2024-12-18 Affibody AB Protein z variants binding thymic stromal lymphopoietin and their medical use
CA3253643A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. BORON-CONTAINING COMPOUNDS, AROMATICS AND ASSOCIATED INSULIN ANALOGUES
CN119677787A (zh) 2022-08-10 2025-03-21 兴和株式会社 亲和体微胞药物复合体
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
CN121038816A (zh) 2023-05-04 2025-11-28 阿菲博迪公司 新多肽
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025158010A1 (en) 2024-01-25 2025-07-31 Affibody Ab Her2-binding polypeptide
CN121041473A (zh) * 2024-05-29 2025-12-02 烟台蓝纳成生物技术股份有限公司 一种双功能性融合蛋白、放射性核素标记物及其应用
CN118666961B (zh) * 2024-08-23 2024-11-26 通化安睿特生物制药股份有限公司 人白蛋白特异结合多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) * 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
EP2380594B1 (en) 2004-04-06 2019-12-04 Affibody AB Use of a serum albumin binding peptide to reduce the immunogenicity of a protein
EP2899277A1 (en) * 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2008281913B2 (en) * 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
WO2011056124A1 (en) * 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides

Similar Documents

Publication Publication Date Title
JP2010534486A5 (enExample)
TW496870B (en) Compositions methods for stimulating megakaryocyte growth and differentiation
JP2009540831A5 (enExample)
TWI250988B (en) Thrombopoietic compounds
JP2009519013A5 (enExample)
JP2018522563A5 (enExample)
JP2013127002A5 (enExample)
RU2012114662A (ru) Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина
JP2006149365A5 (enExample)
JP2014526881A5 (enExample)
JP2015509707A5 (enExample)
JP2016052315A5 (enExample)
JP2010513506A5 (enExample)
JP2008535800A5 (enExample)
JP2010518079A5 (enExample)
JP2017538401A5 (enExample)
JP2012522529A5 (enExample)
JP2017529059A5 (enExample)
JP2010516252A5 (enExample)
JP2019501647A5 (enExample)
JP2018532725A5 (enExample)
JP2010538005A5 (enExample)
JP2011530599A5 (enExample)
JP2012529272A5 (enExample)
JP2013504589A5 (enExample)